Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Home > News and Publications > JHM Publications > Promise and Progress > Reprogramming Cancer Cells - The Story of Epigenetics
Promise and Progress - The Key to Safe Bone Marrow Transplants Revealed
Reprogramming Cancer Cells - The Story of Epigenetics
Issue No. 1
Issue No. 1
The Key to Safe Bone Marrow Transplants Revealed
Date: July 16, 2014
Science Translational Medicine, November 2013
Bone marrow transplant researchers provided greater insight into how the chemotherapy drug cyclophosphamide prevents graft-versus-host disease (GVHD) in patients after bone marrow transplantation (BMT). (GVHD is a serious, life-threatening complication of BMT in which the transplanted immune cells attack the patient’s tissue and organs.) BMT researchers Leo Luznik, M.D., Christopher Kanakry, M.D., and team found that regulatory T cells, a certain type of immune cell responsible for curbing GVHD, are protected from cyclophosphamide by expressing high levels of the enzyme aldehyde dehydrogenase (ALDH) after BMT
Richard Jones, M.D. revealed in the 1980s that cells containing ALDH evade the toxic effects of cyclophosphamide and reconstitute the patient’s immune system. Building upon this work, Drs. Luznik and Kanakry found that in BMT, regulatory T-cells also use ALDH to resist cyclophosphamide and that this persistence of regulatory T cells after cyclophosphamide treatment is necessary for the GVHD protective effects of this approach.
More than a decade ago Drs. Luznik and Ephraim Fuchs, M.D., found that high doses of cyclophosphamide thwarted acute and chronic GVHD, and more recently have used it to safely administer half-matched bone marrow transplants, a procedure once impossible due to terribly high rates of life-threatening immune reactions. This research fills in an important piece of the puzzle in understanding how post-transplant cyclophosphamide works to prevent GVHD. The team is building upon these findings to study methods to improve the treatment.
The research was funded by the National Institutes of Health’s National Cancer Institute and National Heart. Lung, and Blood Institute grants HL 110907, CA 122779, CA 15396, UL 1-RR025005, and HL007525, the Conquer Cancer Foundation of the American Society of Clinical Oncology, and Otsuka Pharmaceutical.
Articles in this Issue
- Headline Makers - Overview
- A Safer Way to Treat Pediatric Brain Cancers
- For Cervical Lesions, Tissue Exam Beats Conventional Blood Tests
- Blood Cells Transformed to Repair Damaged Retina
- Personalized Chemotherapy
- 3D Scans Show whether Treatment is Working
- Alcohol Metabolite Could Increase Cancer Risk in Some People
- Acupuncture, Real or Simulated, Eases Hot Flashes
- New Leukemia Findings
- HPV Oral Cancers and Risk of Infection for Couples
- Molecular Marker of Cancer Drug Response
- Chronic Inflammation Connected to Prostate Cancer
- Fat Versus Brain Cancer
- DNA Damaging Toxins In Food
- Cancer Patients Who Quit Smoking Live Longer
- New Immune Therapy Shows Promise Against Melanoma
- Breathe Easier and Fight Cancer
- Cost-Cutting and Excellent Care Not Mutuallly Exclusive
- The Key to Safe Bone Marrow Transplants Revealed